Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)

Inclusion Criteria:

• Histologically or cytologically confirmed pancreatic cancer

• Male or female participants who are at least 18 years of age on the day of signingin-formed consent

• Borderline resectable tumor (see table 1 for definitions of resectability)

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Ability to undergo surgery, radiotherapy and chemotherapy

• Leucocytes (WBC) ≥ 3.0 X 109/l

• Platelets ≥ 100X 109 /l

• Hemoglobin ≥ 6 mmol/l

• Renal function: E-GFR > 50 ml/min

• Bilirubin < 50 µmol/l or planned for biliary drainage

• A male participant must agree to use a contraception as detailed in Appendix 5 ofthis protocol during the treatment period and for at least 18 weeks after the lastdose of study treatment and refrain from donating sperm during this period.

• A female participant is eligible to participate if she is not pregnant (see Appendix 5), not breastfeeding, or a woman of childbearing potential (WOCBP) who agrees tofollow the contraceptive guidance during the treatment period and for at least 18weeks after the last dose of study treatment.

• Written informed consent

Exclusion Criteria:

• Metastatic or locally advanced (i.e. unresectable) pancreatic cancer.

• Ampullary or distal bile duct cancer.

• Serious concomitant systemic disorders that would compromise the safety of thepatient or his/her ability to complete the study, at the discretion of theinvestigator.

• Complete dihydropyrimidine dehydrogenase deficiency.

• A WOCBP who has a positive urine pregnancy test within 72 hours prior to start oftreatment / (see Appendix 5). If the urine test is positive or cannot be confirmedas negative, a serum pregnancy test will be required.

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or antiPDL2 agent or withan agent directed to another stimulatory or co-inhibitory T-cell receptor (eg,CTLA-4, OX40, CD137).

• Has received prior systemic anti-cancer therapy including investigational agents forpancreatic cancer.

• Has received prior radiotherapy within 2 weeks of start of study intervention.

• Has received a live vaccine within 30 days prior to the first dose of study drug.Examples of live vaccines include, but are not limited to, the following: measles,mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, BacillusCalmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines forinjection are generally killed virus vaccines and are allowed; however, intranasalinfluenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.COVID vaccines are allowed.

• Is currently participating in or has participated in a study of an investigationalagent or has used an investigational device within 4 weeks prior to the first doseof study intervention.

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroidthera-py (in dosing exceeding 10 mg daily of prednisone equivalent) or any otherform of immunosuppressive therapy within 7 days prior to the first dose of studydrug

• Has a known additional malignancy that is progressing or has required activetreat-ment within the past 2 years. Participants with basal cell carcinoma of theskin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breastcarcinoma, cervical cancer in situ) that have undergone potentially curative therapyare not excluded

• Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of itsexcipients.

• Has active autoimmune disease that has required systemic treatment in the past 2years (i.e. with use of disease modifying agents, corticosteroids orimmunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, orphysiologic corticosteroid replacement therapy for adrenal or pituitaryinsufficiency, etc.) is not considered a form of systemic treatment and is allowed.

• Has a history of (non-infectious) pneumonitis that required steroids or has cur-rentpneumonitis.

• Has an active infection requiring systemic therapy.

• Has a known history of Human Immunodeficiency Virus (HIV) infection.

• Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]reactive) or known active Hepatitis C virus infection.

• Has a history or current evidence of any condition, therapy, or laboratoryabnormality that might confound the results of the study, interfere with theparticipant's participation for the full duration of the study, or is not in thebest interest of the participant to participate, in the opinion of the treatinginvestigator.

• Has known psychiatric or substance abuse disorders that would interfere withcooperation with the requirements of the trial.

• Is pregnant or breastfeeding or expecting to conceive or father children within theprojected duration of the study, starting with the screening visit through 120 daysafter the last dose of trial treatment.

• Has had an allogenic tissue/solid organ transplant.

• Has contra-indications for MRI (only for Amsterdam UMC and UMC Utrecht)treatment / (see Appendix 5). If the urine test is positive or cannot be confirmed
as negative, a serum pregnancy test will be required.
 

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or antiPDL2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg,
CTLA-4, OX40, CD137).
 

• Has received prior systemic anti-cancer therapy including investigational agents for
pancreatic cancer.
 

• Has received prior radiotherapy within 2 weeks of start of study intervention.
 

• Has received a live vaccine within 30 days prior to the first dose of study drug.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for
injection are generally killed virus vaccines and are allowed; however, intranasal
influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
COVID vaccines are allowed.
 

• Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose
of study intervention.
 

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid
thera-py (in dosing exceeding 10 mg daily of prednisone equivalent) or any other
form of immunosuppressive therapy within 7 days prior to the first dose of study
drug
 

• Has a known additional malignancy that is progressing or has required active
treat-ment within the past 2 years. Participants with basal cell carcinoma of the
skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast
carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
are not excluded
 

• Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its
excipients.
 

• Has active autoimmune disease that has required systemic treatment in the past 2
years (i.e. with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
 

• Has a history of (non-infectious) pneumonitis that required steroids or has cur-rent
pneumonitis.
 

• Has an active infection requiring systemic therapy.
 

• Has a known history of Human Immunodeficiency Virus (HIV) infection.
 

• Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
reactive) or known active Hepatitis C virus infection.
 

• Has a history or current evidence of any condition, therapy, or laboratory
abnormality that might confound the results of the study, interfere with the
participant's participation for the full duration of the study, or is not in the
best interest of the participant to participate, in the opinion of the treating
investigator.
 

• Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
 

• Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of trial treatment.
 

• Has had an allogenic tissue/solid organ transplant.
 

• Has contra-indications for MRI (only for Amsterdam UMC and UMC Utrecht)

• Pacemakers or implanted defibrillators, deep brain stimulators, cochlearim-plants.

• Patients who have a metallic foreign body in their eye, or who have ananeu-rysm clip in their brain, cannot have an MRI scan since the magnetic fieldmay dislodge the metal.

• Patients with severe claustrophobia not able to tolerate an MRI scan